OBJECTIVE: To provide population-based incidence estimates for constituent symptoms of human immundeficiency virus (HIV)-related lipodystrophy syndrome and to identify possible independent predictors of accrued cases. DESIGN: Prospective population-based cohort. Methods Study subjects were antiretroviral-naïve individuals who initiated treatment between October 1998 and May 2001 and provided completed self-reported data regarding the occurrence of lipoatrophy, lipohypertrophy and increased triglyceride and cholesterol levels. Possible predictors of incident lipoatrophy, lipohypertrophy, dyslipidaemia and mixed lipodystrophy (symptoms of both lipoatrophy and lipohypertrophy) were identified using logistic regression modelling. A sub-analysis restricted to subjects retaining original treatment at study completion was conducted using similar methods. RESULTS: Among the 366 study subjects, cumulative incidence was 29% for lipoatrophy, 23% for lipohypertrophy, 9% for dyslipidaemia, and 13% for mixed lipodystrophy after a median duration of 12 months of antiretroviral therapy. In an intentto-treat analysis incident lipoatrophy and lipohypertrophy were independently associated with initiation of protease inhibitor (PI)-containing regimens, (adjusted odds ratio [AOR] = 1.94; 95% CI: 1.25-3.03 and AOR = 1.76; 95% CI: 1.09-2.85, respectively) and female gender (AOR = 2.06; 95% CI: 1.03-4.12 and AOR = 2.36; 95% CI: 1.17-4.74, respectively). Both mixed lipodystrophy and reported dyslipidaemia were associated only with PI inclusion in the initial regimen (AOR = 2.27; 95% CI: 1.14-4.53 and AOR = 2.14; 95% CI: 1.26-3.65, respectively). Similar results were obtained in analysis of individuals retained in initial treatment groups throughout follow-up. CONCLUSION: Incident morphological and lipid abnormalities are common among individuals initiating first-time antiretroviral therapy. Use of PI was consistently associated with all lipodystrophy-related abnormalities after adjustment for a broad range of patient personal, clinical and treatment characteristics.
OBJECTIVE: To provide population-based incidence estimates for constituent symptoms of human immundeficiency virus (HIV)-related lipodystrophy syndrome and to identify possible independent predictors of accrued cases. DESIGN: Prospective population-based cohort. Methods Study subjects were antiretroviral-naïve individuals who initiated treatment between October 1998 and May 2001 and provided completed self-reported data regarding the occurrence of lipoatrophy, lipohypertrophy and increased triglyceride and cholesterol levels. Possible predictors of incident lipoatrophy, lipohypertrophy, dyslipidaemia and mixed lipodystrophy (symptoms of both lipoatrophy and lipohypertrophy) were identified using logistic regression modelling. A sub-analysis restricted to subjects retaining original treatment at study completion was conducted using similar methods. RESULTS: Among the 366 study subjects, cumulative incidence was 29% for lipoatrophy, 23% for lipohypertrophy, 9% for dyslipidaemia, and 13% for mixed lipodystrophy after a median duration of 12 months of antiretroviral therapy. In an intentto-treat analysis incident lipoatrophy and lipohypertrophy were independently associated with initiation of protease inhibitor (PI)-containing regimens, (adjusted odds ratio [AOR] = 1.94; 95% CI: 1.25-3.03 and AOR = 1.76; 95% CI: 1.09-2.85, respectively) and female gender (AOR = 2.06; 95% CI: 1.03-4.12 and AOR = 2.36; 95% CI: 1.17-4.74, respectively). Both mixed lipodystrophy and reported dyslipidaemia were associated only with PI inclusion in the initial regimen (AOR = 2.27; 95% CI: 1.14-4.53 and AOR = 2.14; 95% CI: 1.26-3.65, respectively). Similar results were obtained in analysis of individuals retained in initial treatment groups throughout follow-up. CONCLUSION: Incident morphological and lipid abnormalities are common among individuals initiating first-time antiretroviral therapy. Use of PI was consistently associated with all lipodystrophy-related abnormalities after adjustment for a broad range of patient personal, clinical and treatment characteristics.
Authors: Jordan E Lake; Grace A McComsey; Todd M Hulgan; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; M Sean Boger; Ralph R Turner; Heather E McCreath; Judith S Currier Journal: AIDS Patient Care STDS Date: 2012-07-23 Impact factor: 5.078
Authors: Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine Journal: Toxicol Pathol Date: 2009-01-26 Impact factor: 1.902
Authors: Arif Alibhai; Walter Kipp; L Duncan Saunders; Ambikaipakan Senthilselvan; Amy Kaler; Stan Houston; Joseph Konde-Lule; Joa Okech-Ojony; Tom Rubaale Journal: Int J Womens Health Date: 2010-08-09
Authors: Carine S Andrade; Rosângela P Jesus; Taciana B Andrade; Neyara S Oliveira; Scott A Nabity; Guilherme S Ribeiro Journal: PLoS One Date: 2012-11-07 Impact factor: 3.240
Authors: Eric Walter Pefura Yone; Awa Foueudjeu Betyoumin; André Pascal Kengne; François Jérome Kaze Folefack; Jeanne Ngogang Journal: AIDS Res Ther Date: 2011-09-26 Impact factor: 2.250
Authors: Zhihui Dou; Jiahong Xu; Jin Hua Jiao; Ye Ma; Stephen Durako; Lan Yu; Yan Zhao; Fujie Zhang Journal: PLoS One Date: 2011-08-16 Impact factor: 3.240
Authors: Vicente Estrada; Paloma Geijo; Manuel Fuentes-Ferrer; María Luisa García Alcalde; María Rodrigo; María José Galindo; Agustín Muñoz; Pere Domingo; Esteve Ribera; Jaime Cosín; Pompeyo Viciana; Fernando Lozano; Alberto Terrón; Antonio Vergara; Ramón Teira; Josefa Muñoz-Sánchez; Bernardino Roca; Trinitario Sánchez; José López-Aldeguer; Elisabeth Deig; Francisco Vidal; Enric Pedrol; Manuel Castaño-Carracedo; Teresa Puig; Myriam Garrido; Ignacio Suárez-Lozano Journal: BMC Womens Health Date: 2011-08-04 Impact factor: 2.809
Authors: Lismeia Raimundo Soares; Daniela Cardeal da Silva; Claudio R Gonsalez; Felipe G Batista; Luiz Augusto M Fonseca; Alberto J S Duarte; Jorge Casseb Journal: Rev Inst Med Trop Sao Paulo Date: 2015 Mar-Apr Impact factor: 1.846